We have had quite a journey in these 24 years! Sit back and travel through our major milestones.
Incorporation of our Company
Our R&D arm, Bigtec Private Limited, one of our Subsidiaries commenced its operations.
Entered into a joint venture agreement dated August 1, 2011 with Bigtec Innovations Private Limited and Bigtec Private Limited
In 2015, Molbio Diagnostics and Bigtec Labs merged, marking a new era in MedTech innovation. This strategic move transformed Bigtec into Molbio’s dedicated R&D wing, strengthening its diagnostics and technological development capabilities. With Bigtec driving innovation and Molbio ensuring rapid market adoption, they reinforce their shared vision of revolutionizing global healthcare.
In 2015, the H1N1 outbreak affected nearly 30,000 people in India. As a multi-disease real-time PCR, Truenat demonstrated its capabilities as a technology solution that can adapt itself to disease outbreaks within no time. With rapid and precise testing at the point of care, it played a crucial role in early diagnosis and containment, effectively cutting down the chain of transmission and becoming a silent warrior in the fight against the epidemic.
In 2016, India reeled under a massive outbreak of Chikungunya, with 64,057 confirmed cases across the country. Truenat, as a multi-disease platform, was utilized to deliver rapid results ensuring early detection and infection control, proving itself as an innovation that is adaptable and future-ready.
Launch of fully- automatic PCR device ‘Truelab Uno” and approved by the Indian Council for Medical Research (“ICMR”)
Investment by V Sciences Investments Pte. Ltd in the Company.
Truenat became part of innovations rolled out under the Introducing New Tools Project (iNTP), a collaboration between USAID, and the Stop TB Partnership across 11 TB high-burden countries. Molbio also began collaborating with the Global Fund, a multilateral funding agency for global health that pools the world’s resources to invest strategically in programs to fight major killers in low—and middle-income countries: HIV, tuberculosis (TB), and malaria. To date, Molbio holds long-term agreements with both the United Nations and the Global Fund allowing countries to quickly access its products.
Launched ‘Edge’, a scaleup partnership initiative between our Company and Bigtec
Investment of 19.68% of the paid-up equity share capital of Optrascan, INC to diversify to digital pathology scanners
Molbio recognizes the importance of a level playing field for innovations and introduced the EDGE Program- a program designed to bridge the critical gaps between innovation and market adoption for point-of-need diagnostic technologies by integrating experience, expertise, and state-of-the-art facilities. The program aims to foster collaboration with researchers, healthcare professionals, and industry leaders to accelerate groundbreaking technology solutions.
Connect with us
Molbio Diagnostics Limited
(Formerly Molbio Diagnostics Private Limited)
© All Rights Reserved
